Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765883 in advanced pancreatic cancer
NCT06528093Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of BI 765883 in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Dose-Limiting Toxicities at 35 days. Started Oct 2024; status: terminated.
02
Drugs
BI 765883
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06528093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528093.